International Scholarly Research Notices / 2012 / Article / Tab 2 / Clinical Study
High Dose Infliximab in the Treatment of Refractory Uveitis: Does Dose Matter? Table 2 Comparison of ocular findings of patients treated with high-dose, moderate-dose, and low-dose infliximab at baseline examination and at one-year followup.
ACD Flare Visual acuity IOP Patient Baseline 12 month Baseline 12 month Baseline 12 month Baseline 12 month OS OD OS OD OS OD OS OD OS OD OS OD OS OD OS OD HD 1 2+ 2+ 0 0 3+ 1+ 1+ 0 HM 8ft/200 HM 1ft/200 H H H N 2 3+ 0 1+ 0 3+ 2+ 1+ 0 HM 20/20 HM 20/20 H N H N 3 2+ 2+ 2+ 1+ 1+ 1+ 1+ 0 20/60 20/30 20/100 20/60 H H N N 4 2+ 2+ 1+ 1+ 3+ 2+ 0 0 20/800 20/800 20/20 20/70 H H N N 5 2+ 2+ 0 0 0 1+ 0 0 20/400 20/20 20/20 20/20 H N H N 6 2+ 2+ 2+ 2+ 3+ 3+ 1+ 1+ 20/125 5ft/400 20/125 HM N H N H 7 2+ 1+ 0 0 1+ 2+ 0 0 LP 20/200 LP 20/80 H N H N 8 3+ 3+ 0 0 3+ 3+ 0 0 20/400 20/200 20/40 20/40 H H N N 9 1+ 2+ 2+ 2+ 2+ 2+ 1+ 1+ 20/300 20/40 20/200 20/100 H N N N MD 10 2+ 2+ 0 0 2+ 2+ 0 0 20/60 20/40 20/40 20/40 N N N N 11 1+ 1+ 0 0 2+ 1+ 0 0 20/400 20/30 20/50 20/20 H N H N 12 1+ 1+ 0 0 1+ 1+ 0 0 20/30 20/40 20/30 20/30 N H N N 13 3+ 2+ 1+ 1+ 2+ 2+ 1+ 1+ 20/25 20/25 20/20 20/20 H N N N 14 1+ 1+ 0 0 2+ 2+ 0 0 20/25 20/25 20/20 20/25 H N N N 15 2+ 2+ 0 0 1+ 1+ 0 0 20/30 20/30 20/20 20/20 N N N N 16 2+ 2+ 2+ 1+ 2+ 3+ 0 0 20/25 20/40 20/20 20/60 H N N N 17 2+ 2+ 1+ 1+ 1+ 1+ 0 0 20/100 20/20 20/60 20/20 N N N N 18 2+ 2+ 1+ 1+ 2+ 2+ 0 1+ 20/100 20/200 20/60 20/400 N N N H 19 2+ 2+ 1+ 1+ 1+ 1+ 0 0 20/200 20/200 20/200 20/200 N N N N 20 1+ 1+ 1+ 1+ 1+ 1+ 0 0 20/80 LP 20/40 LP N H N H 21 2+ 2+ 0 0 2+ 3+ 0 0 20/20 20/400 20/40 20/200 N N N N 22 2+ 2+ 0 0 2+ 2+ 0 0 20/200 20/200 20/40 20/40 H N N N 23 3+ 3+ 0 0 2+ 2+ 0 0 20/20 20/40 20/20 20/20 N N N N 24 NA 2+ NA 0 0 1+ 0 0 20/40 20/200 20/40 20/40 N N N N 25 1+ 1+ 0 0 2+ 1+ 0 0 20/60 20/40 20/20 20/20 N N N N 26 2+ 2+ 0 0 2+ 2+ 0 0 20/20 20/40 20/20 20/20 N N N N 27 1+ 1+ 0 0 2+ 2+ 0 0 20/80 20/20 20/60 20/20 N N N N 28 2+ 2+ 0 0 1+ 1+ 0 1+ 20/20 20/20 20/20 20/20 N N N N LD 29 2+ 1+ 0 0 3+ 2+ 0 0 20/100 20/20 20/20 20/20 N N N N 30 1+ 1+ 0 0 0 1+ 0 0 20/20 20/80 20/20 20/30 N N N N 31 2+ 2+ 0 0 2+ 2+ 0 0 20/40 20/30 20/80 20/30 N N N N 32 2+ 1+ 0 0 1+ 1+ 0 0 20/20 20/20 20/20 20/20 N N N N 33 1+ 2+ 0 0 1+ 2+ 0 0 20/20 20/20 20/20 20/20 N N N N 34 1+ 2+ 0 0 1+ 2+ 0 0 20/20 20/20 20/20 20/20 N N N N
HD-high dose; MD-moderate dose; LD-low dose; ACD-anterior chamber cell density; IOP-intraocular pressure; LP-light perception; HM-hand movement; N-normal; H-high; Ft-feet; OS-ocular sinister; OD-oculus dexter.
